Medicare GLP-1 Coverage: Everything Changing in July 2026

Medicare will cover Wegovy and Zepbound for weight loss at a flat $50/month copay starting July 2026, through the Medicare GLP-1 Bridge Demonstration program. Approximately 3.4 million Medicare beneficiaries. Use our insurance coverage lookup to check your specific plan, or compare all 40 providers to find one that accepts Medicare are expected to qualify. The Medicare GLP-1 Bridge Demonstration, announced by CMS on December 23, 2025, represents the first time Medicare has covered weight loss drugs since Part D began in 2006. Here's everything you need to know.

What Does the Medicare GLP-1 Bridge Program Cover?

• •Launch date: July 2026
• •Your cost: $50/month copayment
• •Medications covered: Wegovy (semaglutide) and Zepbound (tirzepatide)
• •Negotiated manufacturer price: $245/month (paid by the program)
• •Who qualifies: Medicare Part D enrollees meeting BMI and related health condition criteria
• •Estimated eligible population: ~10% of Medicare beneficiaries

This is a significant shift. Until now, Medicare Part D explicitly excluded weight loss drugs. Coverage was only available for GLP-1s prescribed for Type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea — not weight management alone.

How Does Medicare GLP-1 Pricing Work?

The pricing structure came from a Most-Favored-Nation deal between the Trump administration and both Novo Nordisk and Eli Lilly. Both manufacturers agreed to a net price of $245/month — roughly 75-80% below the retail list price.

For context, Wegovy lists at approximately $1,349/month and Zepbound at about $1,086/month. The $245 negotiated price represents the lowest official price point for brand-name GLP-1s anywhere in the US system.

Additionally, the Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap (effective since 2025) provides a backstop — even if you use other medications, your total annual prescription spending is capped.

Who Qualifies for Medicare GLP-1 Coverage?

To qualify for the Medicare GLP-1 Bridge, you'll need:

• •Active Medicare Part D enrollment
• •BMI of 30 or higher, OR BMI of 27+ with at least one weight-related condition
• •Related health conditions may include Type 2 diabetes, hypertension, cardiovascular disease, sleep apnea, and others
• •Prescription from a qualifying provider

Specific enrollment details and participating pharmacies are expected to be announced by CMS in the months leading up to the July launch.

What Comes After: The BALANCE Model

The Bridge program is temporary — designed to provide immediate access while the larger BALANCE Model rolls out. BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is a voluntary CMS demonstration that combines GLP-1 coverage with lifestyle supports.

• •Medicare Part D plans can participate starting January 2027
• •State Medicaid agencies can opt in starting May 2026
• •CMS will negotiate drug pricing on behalf of all participating plans and states
• •The program includes behavioral health, nutrition counseling, and other lifestyle components alongside medication

What to Do Now

If you're on Medicare and interested in GLP-1 treatment for weight loss, here's what you can do before July 2026:

• •Talk to your doctor about whether you're a candidate based on BMI and health conditions
• •Ensure your Medicare Part D plan is active and current
• •If you have a diabetes diagnosis, your doctor may already be able to prescribe GLP-1s under existing coverage
• •Watch for CMS announcements about specific enrollment procedures as July approaches
• •Check if your current Part D plan has announced participation in the BALANCE Model for 2027